HSBC analysts adjusted their price target on Eli Lilly and Co. to $850 from $800, while maintaining their "Hold" rating on the company's shares. This change reflects an updated valuation perspective from the financial institution on the pharmaceutical giant. The revision comes amid a period of significant attention on Eli Lilly, largely due to the strong market performance of its GLP-1 drugs for diabetes and weight loss. The maintained "Hold" rating suggests that while the price target has increased, the bank's analysts may see the company's current stock price as largely reflecting its strong growth prospects. There was no specific market reaction analysis available regarding this price target change.